DECISION 试验:心力衰竭患者停用地高辛后的临床恶化风险
DECISION 试验预先设定分析评估了射血分数降低或轻度降低的心力衰竭患者在优化指南指导药物治疗后盲法停用地高辛或安慰剂的结局。停药后 6 周内,地高辛停药组心血管死亡或心力衰竭恶化事件发生率显著高于安慰剂停药组。结果提示长期服用地高辛后停药与临床恶化相关,停用需谨慎。
要点
- 地高辛停药后 6 周内心衰恶化事件明显增加,停药需谨慎。
- 停药后心率升高、收缩压降低、NT-proBNP 升高。
- 适用于射血分数降低或轻度降低的心衰患者。
核心结论
- 长期治疗后的地高辛停药与射血分数降低或轻度降低心力衰竭患者的临床恶化相关。
- 停止地高辛时需保持谨慎。
研究设计与样本
- DECISION 试验的预先设定分析,1001 例心衰患者随机接受低剂量地高辛或安慰剂治疗,中位治疗时间 36.5 个月。
- 治疗结束时 587 例仍在积极治疗的患者(地高辛 288 例,安慰剂 299 例)接受盲法停药,并在 6 周时进行面对面随访。
- 所有事件均经裁定。
主要发现
- 停药前 100 天内,地高辛组与安慰剂组心血管死亡或心衰恶化事件发生率分别为 5.7 与 6.5 次/100 患者年,率比 0.88,95%CI 0.24–3.10。
临床怎么用
- 对于射血分数降低或轻度降低且长期服用地高辛的心衰患者,若无明确指征不应随意停用地高辛。
- 停用地高辛后 6 周内应密切监测心衰症状、心率、血压和 NT-proBNP。
局限性
- 停药后随访时间仅 6 周,不能反映更长期的停药效应。
- 原文为 DECISION 试验的预先设定分析,未提供本分析样本量重新估算依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Whether digoxin withdrawal is safe in patients with heart failure (HF) optimized on contemporary guideline-recommended medical therapy remains unknown. This pre-specified analysis of the DECISION trial evaluated outcomes following blinded withdrawal of digoxin or placebo. METHODS: In DECISION, 1001 patients were randomized to low-dose digoxin or placebo and treated for a median of 36.5 months. At the end of the study, 587 patients on active treatment (digoxin 288 and placebo 299) underwent blinded withdrawal with an in-person follow-up visit at 6 weeks. All events were adjudicated. RESULTS: During the pre-withdrawal phase (100 days), incidence rates of cardiovascular (CV) death or worsening HF events were 5.7 vs 6.5 events per 100 patient-years in the digoxin vs placebo group; rate ratio (RR) 0.88; 95% confidence interval (CI) [0.24-3.10]. Following withdrawal, the incidence rate increased markedly in patients withdrawn from digoxin but not placebo (42.8 vs 5.9 events per 100 patient-years; time period-by-treatment interaction, P = .036). Fourteen events (12 hospitalizations and 2 urgent HF visits) occurred in the digoxin withdrawal arm vs two (one HF hospitalization and one CV death) in the placebo withdrawal arm (RR 7.37, 95% CI 1.56-34.88; P = .012). Withdrawal of digoxin was accompanied by an increase in heart rate (P = .003), reduction in systolic blood pressure (P = .014), and rise in NT-proBNP (P = .002). CONCLUSIONS: Discontinuation of digoxin after long-term treatment is associated with clinical deterioration in patients with HF and a reduced or mildly reduced ejection fraction. These findings warrant caution when stopping digoxin.
引用
- van der Meer, van Veldhuisen, Voordes, et al. Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial. Eur Heart J. 2026. PMID: 42106981. doi:10.1093/eurheartj/ehag385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。